Your browser is no longer supported. Please, upgrade your browser.
Settings
ABBV AbbVie Inc. daily Stock Chart
ABBV [NYSE]
AbbVie Inc.
IndexS&P 500 P/E23.22 EPS (ttm)2.78 Insider Own0.10% Shs Outstand1.48B Perf Week-1.75%
Market Cap95.36B Forward P/E6.96 EPS next Y9.25 Insider Trans7.49% Shs Float1.48B Perf Month-5.60%
Income4.18B PEG5.66 EPS next Q2.29 Inst Own70.80% Short Float2.99% Perf Quarter-18.92%
Sales32.62B P/S2.92 EPS this Y4.80% Inst Trans0.08% Short Ratio4.30 Perf Half Y-20.31%
Book/sh-5.79 P/B- EPS next Y4.18% ROA6.80% Target Price85.25 Perf Year-33.88%
Cash/sh3.66 P/C17.61 EPS next 5Y4.10% ROE-58.90% 52W Range62.66 - 100.23 Perf YTD-30.11%
Dividend4.28 P/FCF14.28 EPS past 5Y7.60% ROI21.80% 52W High-35.72% Beta0.93
Dividend %6.64% Quick Ratio0.80 Sales past 5Y11.80% Gross Margin77.40% 52W Low2.82% ATR1.54
Employees30000 Current Ratio0.90 Sales Q/Q-0.30% Oper. Margin21.80% RSI (14)37.36 Volatility2.36% 2.20%
OptionableYes Debt/Eq- EPS Q/Q-60.60% Profit Margin12.50% Rel Volume0.76 Prev Close62.98
ShortableYes LT Debt/Eq- EarningsJul 26 BMO Payout148.90% Avg Volume10.28M Price64.43
Recom2.50 SMA20-2.36% SMA50-8.98% SMA200-19.12% Volume7,792,906 Change2.30%
Jun-27-19Upgrade Wolfe Research Underperform → Peer Perform
Jun-26-19Upgrade SVB Leerink Mkt Perform → Outperform $88
May-28-19Initiated Goldman Neutral
Apr-29-19Upgrade BMO Capital Markets Underperform → Market Perform
Mar-25-19Downgrade Argus Buy → Hold
Jan-23-19Initiated UBS Neutral $91
Jan-03-19Downgrade BofA/Merrill Buy → Neutral
Dec-26-18Initiated Standpoint Research Buy
Oct-22-18Reiterated SunTrust Buy $157 → $135
Oct-04-18Reiterated BofA/Merrill Buy $107 → $106
Jun-01-18Downgrade Piper Jaffray Overweight → Neutral
May-30-18Downgrade Credit Suisse Neutral → Underperform
Jan-30-18Reiterated Morgan Stanley Equal-Weight $99 → $131
Jan-29-18Downgrade Leerink Partners Outperform → Mkt Perform
Oct-30-17Reiterated Leerink Partners Outperform $108 → $107
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Aug-16-19 04:25PM  How AbbVie Plans To Take On Pfizer, Lilly And Kick Its Humira Habit Investor's Business Daily
04:20PM  How Merck Could Ride 'The Keytruda Wave' To Dominate These Rivals Investor's Business Daily
02:06PM  FDA approves AbbVie's Rinvoq to treat moderate-to-severe RA MarketWatch
01:35PM  AbbVie Stock Is Poised To Become A Top 5 Pharma But Should You Buy It? Investor's Business Daily
12:49PM  UPDATE 2-AbbVie prices new rheumatoid arthritis drug at $59,000/yr Reuters
12:43PM  AbbVie Receives FDA Approval of RINVOQ (upadacitinib), an Oral JAK Inhibitor For The Treatment of Moderate to Severe Rheumatoid Arthritis PR Newswire
09:19AM  Gilead's (GILD) Filgotinib MAA for RA Accepted in Europe Zacks
Aug-15-19 03:36PM  The Top Pharma Stocks for 2019 Investopedia
01:49PM  13 High-Yield Dividend Stocks to Watch Kiplinger
Aug-14-19 09:00PM  5 Top Cancer-Fighting Stocks to Buy Now Motley Fool
05:17PM  How Tesla has Become Most Profitable Short Bet at $2.75 Billion Investopedia
09:24AM  Lilly's Taltz Outshines J&J's Tremfya in Psoriasis Study Zacks
07:59AM  Correction: Allergan sale Financial Times
05:00AM  Defensive Stocks on Sale Morningstar
12:00AM  Elliott bags Goldmans Barg Financial Times
Aug-13-19 09:35AM  Should Value Investors Consider AbbVie (ABBV) Stock Now? Zacks
06:00AM  5 Biggest New Drugs Approved in 2019 So Far Motley Fool
01:04AM  JPMorgan Chase set to scoop record fee for Allergan sale Financial Times
Aug-12-19 12:12PM  10 Medical Marijuana Stocks to Cure Your Portfolio InvestorPlace
07:40AM  3M Stock Isnt Crumbling, but Its No Bargain Either InvestorPlace
05:00AM  5 Big Pharma Showdowns to Watch Barrons.com
Aug-11-19 09:00AM  3 Embarrassingly Cheap Dividend Stocks Motley Fool
08:14AM  3 Top Stocks With High Dividend Yields Motley Fool
07:00AM  AbbVie Insiders Bought Up the Stock as It Traded to New Lows Barrons.com
Aug-09-19 09:50AM  Pharma Stock Roundup: AGN, NVO Earnings, EU Nod to SNY & ABBV Drugs for New Patients Zacks
09:15AM  Why AbbVie (ABBV) is a Great Dividend Stock Right Now Zacks
Aug-08-19 04:30AM  AbbVie: The Right Mixture for the Perfect Stock TheStreet.com
12:37AM  CytomX Therapeutics, Inc. (CTMX) Q2 2019 Earnings Call Transcript Motley Fool
Aug-07-19 12:37PM  Enanta Pharmaceuticals, Inc. (ENTA) Q2 2019 Earnings Call Transcript Motley Fool
Aug-06-19 03:00PM  Allergan Boosts 2019 Guidance While Waiting to be Acquired by AbbVie Motley Fool
01:19PM  Allergan beats second-quarter expectations, boosts full-year guidance MarketWatch
12:01PM  Despite Historic Market Performance, IMX Remains Relatively Unchanged Benzinga
11:56AM  Top Research Reports: Chevron, AbbVie, Phillips 66 & More Zacks
10:19AM  Allergan (AGN) Q2 Earnings & Sales Top, '19 Sales View Up Zacks
09:58AM  Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand Reuters
09:51AM  Allergan beats profit, raises revenue forecast on Restasis, Juvederm demand Reuters
05:37AM  Allergan Tops Q2 Profit Estimate, Lifts 2019 Revenue Guidance After Abbive Deal TheStreet.com
Aug-05-19 10:59AM  Momenta (MNTA) Q2 Loss Wider Than Expected, Revenues Miss Zacks
10:18AM  ImmunoGen (IMGN) Stock Down Despite Q2 Earnings & Sales Beat Zacks
08:30AM  AbbVie Submits New Drug Application to US FDA for Investigational Elagolix for Management of Heavy Menstrual Bleeding Associated with Uterine Fibroids in Women PR Newswire
04:35AM  Big Pharma Sees Pockets of Recent Insider Buying TheStreet.com
Aug-04-19 09:00AM  These 5 Prescription Drugs Will Generate a Jaw-Dropping $62.3 Billion in 2024 Motley Fool
08:01AM  Notable Insider Buys: AbbVie, Bristol-Myers And More Benzinga
Aug-03-19 06:09PM  Weekly Top Insider Buys Highlight for the Week of Aug. 2 GuruFocus.com
Aug-02-19 09:54AM  Pharma Stock Roundup: PFE, MRK, LLY Q2 Earnings, Upjohn-MYL Merger Zacks
Jul-31-19 06:15PM  Abbvie Inc (ABBV) EVP, Chief Strategy Officer Henry O Gosebruch Bought $2 million of Shares GuruFocus.com
02:36PM  Top Marijuana Stocks That Pay Dividends Investopedia
06:10AM  AbbVie (NYSE:ABBV) Shareholders Have Enjoyed A 29% Share Price Gain Simply Wall St.
Jul-30-19 01:14PM  Merck Shares Rise on Strong Sales Growth GuruFocus.com
12:25PM  Why Neurocrine Biosciences Stock Is Jumping Today Motley Fool
11:48AM  Cramer Weighs In On AbbVie, Six Flags And More Benzinga
09:14AM  Dr. Reddy's (RDY) Q1 Earnings and Revenues Increase Y/Y Zacks
09:02AM  Bayer (BAYRY) Q2 Earnings Match Estimates, Sales Up Y/Y Zacks
08:00AM  The 5 Worst S&P 500 Stocks Are Costing You $22.3 Billion; Here's Why Investor's Business Daily
Jul-29-19 07:02PM  Edited Transcript of ABBV earnings conference call or presentation 26-Jul-19 1:00pm GMT Thomson Reuters StreetEvents
03:05PM  Pfizer to Combine Off-Patent Drug Business With Mylan GuruFocus.com
Jul-28-19 09:47AM  AbbVie stock gets welcome boost from positive earnings MarketWatch
Jul-26-19 06:23PM  AbbVie Inc (ABBV) Q2 2019 Earnings Call Transcript Motley Fool
03:00PM  5 Things You Need to Know From AbbVie's Q2 Earnings Results Motley Fool
12:10PM  AbbVie Earnings: ABBV Stock Pops on Q2 Beat InvestorPlace
12:00PM  AbbVie Discontinued a Drug Trial. Biogen Stock Is Falling. Barrons.com
11:57AM  AbbVie (ABBV) Beats on Q2 Earnings & Sales, Raises EPS View Zacks
11:51AM  AbbVie spotlights Allergan deal, new drugs as Humira sales wane Reuters
11:12AM  AbbVie Reverses 4-Day Dive But Its Biggest Moneymaker Is In Trouble Investor's Business Daily
11:02AM  Bristol-Myers Squibb (BMY) Catches Eye: Stock Jumps 5% Zacks
10:15AM  AbbVie does not expect to divest new psoriasis drug Reuters
09:23AM  AbbVie stock up 2% after earnings beat MarketWatch
09:05AM  AbbVie (ABBV) Tops Q2 Earnings and Revenue Estimates Zacks
09:04AM  UPDATE 3-AbbVie spotlights Allergan deal, new drugs as Humira sales wane Reuters
08:58AM  AstraZeneca (AZN) Jumps: Stock Rises 5.7% Zacks
08:52AM  AbbVie Delivers a Win on Earnings and Raises Profit Forecast Barrons.com
08:27AM  AbbVie raises guidance as cancer treatments boost sales Financial Times
08:01AM  AbbVie (ABBV) Beats Q2 Earnings and Revenues, Shares Up Zacks
07:43AM  AbbVie raises 2019 profit target as quarterly sales beat estimates Reuters
07:42AM  AbbVie Reports Second-Quarter 2019 Financial Results PR Newswire
06:00AM  McDonald's, AbbVie, and Twitter - Earnings to Watch TheStreet.com
04:29AM  [video]AbbVie Rises on Strong Second-Quarter Results, Raised Guidance TheStreet.com
03:44AM  AbbVie Earnings, Revenue Beat in Q2 Investing.com
Jul-25-19 06:52PM  Buy Merck & Co (MRK) Stock Ahead of Q2 Earnings Report? Zacks
03:06PM  Q2 Earnings Outlook For AbbVie Benzinga
12:24PM  AbbVie is committed to the elimination of hepatitis C in Canada by 2030 CNW Group
09:03AM  Zacks.com featured highlights include: Amedisys, AbbVie, Laureate, Genesco and Valeritas Zacks
08:44AM  Should You Buy AbbVie (ABBV) Ahead of Earnings? Zacks
07:25AM  Roche (RHHBY) 1H19 Earnings & Sales Up Y/Y, View Raised Zacks
Jul-24-19 01:54PM  What to Expect from Sanofi's (SNY) Q2 Earnings (Revised) Zacks
12:13PM  What to Expect from Sanofi's (SNY) Q2 Earnings Zacks
11:20AM  AbbVie: A Top Dividend Stock GuruFocus.com
09:44AM  Large-Cap Pharmaceuticals Industry Near-Term Outlook Bright Zacks
09:34AM  Merck (MRK) to Report Q2 Earnings: What's in the Cards? Zacks
09:15AM  Are You Looking for a High-Growth Dividend Stock? AbbVie (ABBV) Could Be a Great Choice Zacks
09:04AM  Eli Lilly (LLY) to Report Q2 Earnings: What's in Store? Zacks
07:15AM  Use Rising P/E Strategy to Buy 5 Winning Stocks Zacks
07:15AM  Celgene, Bristol-Myers and AbbVie still to report earnings this week: Heres what to expect MarketWatch
06:00AM  AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue PR Newswire
06:00AM  3 Top Healthcare Stocks to Buy in July Motley Fool
Jul-23-19 05:41PM  CORRECTED-Samsung Bioepis Humira biosimilar wins FDA approval Reuters
05:36PM  CEO calls it an 'important day for women's health.' Wall Street appears unimpressed American City Business Journals
04:00PM  How to Invest in Cancer-Fighting Stocks Motley Fool
02:03PM  Why Bristol-Myers Squibb Stock Is Stumbling Ahead of Earnings InvestorPlace
11:58AM  AbbVie (ABBV) Set to Report Q2 Earnings: What to Expect Zacks
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behcet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenstrom's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides KALETRA, an anti-human immunodeficiency virus (HIV)-1 medicine used with other anti-HIV-1 medications to maintain viral suppression in HIV-1 patients; NORVIR, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and SYNAGIS to prevent respiratory syncytial virus infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males; CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron to treat prostate cancer, endometriosis, and central precocious puberty, as well as anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product; and ORILISSA, a non-peptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain. It has collaborations with Alector, Inc.; Janssen Biotech, Inc.; Galapagos; Bristol-Myers Squibb Company; and Calico Life Sciences LLC. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
AUSTIN ROXANNE SDirectorAug 01Buy65.6625,0001,641,400117,114Aug 02 05:02 PM
AUSTIN ROXANNE SDirectorJul 31Buy66.0230,0001,980,69092,114Aug 02 05:02 PM
AUSTIN ROXANNE SDirectorJul 30Buy66.3510,000663,50062,114Jul 31 04:46 PM
Gosebruch Henry OEVP, Chief Strategy OfficerJul 29Buy67.2830,0002,018,38575,763Jul 31 04:46 PM
AUSTIN ROXANNE SDirectorJun 26Buy67.5011,500776,25052,114Jun 28 04:47 PM
CHASE WILLIAM JEVP, Finance & AdministrationJun 26Buy67.3030,4002,045,920169,552Jun 28 04:47 PM
RAPP EDWARD JDirectorJun 26Buy67.307,500504,75030,662Jun 28 04:48 PM
Durkin Brian LVP, ControllerMar 25Sale79.6947537,8539,121Mar 25 04:34 PM
Schumacher Laura JVice ChairmanMar 14Sale80.0025,0002,000,000139,838Mar 15 05:53 PM
SALEKI-GERHARDT AZITAEVP, OperationsMar 05Sale79.0315,7971,248,48093,312Mar 06 05:03 PM
Schumacher Laura JVice ChairmanDec 28Sale90.0025,0002,250,000134,322Jan 02 04:49 PM
CHASE WILLIAM JEVP, Finance & AdministrationDec 12Sale90.0060,0005,400,000104,863Dec 14 05:12 PM
GONZALEZ RICHARD AChairman of the Board and CEODec 11Sale88.7516,8501,495,438286,203Dec 13 04:56 PM
Schumacher Laura JExecutive Vice PresidentDec 04Option Exercise51.4294,1404,840,679192,398Dec 07 05:15 PM
Schumacher Laura JExecutive Vice PresidentDec 04Sale93.5894,1408,809,55298,258Dec 07 05:15 PM
Gosebruch Henry OEVP, Chief Strategy OfficerNov 29Sale90.1042,4503,824,94030,350Nov 30 05:22 PM